An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat Allergy Immunotherapy [Cat-PAD]

Trial Profile

An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat Allergy Immunotherapy [Cat-PAD]

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2012

At a glance

  • Drugs Cat SPIRE (Primary) ; Cat SPIRE (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Circassia
  • Most Recent Events

    • 29 Mar 2011 New trial record
    • 29 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top